Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Charles Wagner, Jr., Stephen Jones, Thomas Kean, Melinda Griffith, and More

Premium

GoodStart Genetics has appointed Charles Wagner, Jr., to its board of directors. Wagner is CFO and executive VP of finance and administration at Bruker Corporation. Previously, he held similar positions at Progress Software Corporatio and Millipore Corporation.


MolecularHealth has added several new members to its advisory board, including Stephen Jones, who from 1999 to 2014 served as the medical director of research for US Oncology Research; Thomas Kean, CEO and president of C-Change, a coalition of stakeholders dedicated to eliminating the cancer burden on the US population; and Kathleen Lokay, president and CEO of Via Oncology.


CardioDx announced that Melinda Griffith will be its new head of corporate development and general counsel and Doug Ross will the firm's new chief scientific officer. Griffith has previously held various executive management positions at Clarient, which was acquired by GE Healthcare. Ross served as acting chief scientific officer of Life Technologies' medical science division.

Simultaneously, CardioDx also appointed James Tobin and Andrew Guggenhime to its board of directors. Tobin was previously CEO of Boston Scientific. Meanwhile, Guggenhime is transitioning currently from his role as CFO at CardioDx to its board of directors.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.